期刊
ANNUAL REVIEW OF MEDICINE
卷 61, 期 -, 页码 135-152出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev.med.60.042507.164323
关键词
HIV vaccines; neutralizing antibodies; envelope glycoproteins; immunogenicity
资金
- NIAID NIH HHS [AI074362, AI45378] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045378, R01AI045378, R56AI074362, R01AI074362] Funding Source: NIH RePORTER
Developing an HIV-1 vaccine that can elicit antibodies to prevent infection has been a formidable challenge. Although no single immunogen has generated antibodies that can neutralize diverse isolates, progress has been made in understanding (a) the structure of the HIV-1 envelope glycoprotein, which is targeted by neutralizing antibodies, (b) how HIV-1 evades antibodies made by an infected host, and (c) how rare monoclonal antibodies can exhibit broadly neutralizing activity. Advances in structural and molecular biology coupled with new approaches to isolate neutralizing antibodies from HIV-1-infected individuals are enhancing our understanding of what humoral immune responses will be required for a vaccine. This review summarizes progress in understanding the host antibody response to HIV-1 and current strategies for applying this information to develop an effective vaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据